科前生物(688526) - 2023 Q3 - 季度财报

Financial Performance - The net profit for Q3 2023 was CNY 357,180,085.48, compared to CNY 283,242,940.68 in Q3 2022, reflecting a year-over-year increase of about 26%[5] - Basic earnings per share rose to CNY 0.77, up from CNY 0.61 in the same quarter last year, indicating a growth of approximately 26%[9] - Operating revenue from sales of goods and services for the first nine months of 2023 reached CNY 887,405,231.05, compared to CNY 725,535,478.12 in the same period of 2022, marking an increase of about 22.3%[10] - Total operating revenue for the first three quarters of 2023 reached CNY 827,439,173.94, an increase of 20.53% compared to CNY 686,519,778.45 in the same period of 2022[32] - Net profit attributable to shareholders of the listed company for the first three quarters of 2023 was CNY 357,428,181.10, reflecting a growth of 26.11% year-on-year[32] Assets and Liabilities - The total assets increased to CNY 4,737,743,654.84, up from CNY 4,390,641,791.92, representing a growth of approximately 7.9% year-over-year[4] - The total liabilities increased to CNY 845,705,990.93, up from CNY 623,841,368.92, representing a growth of approximately 35.5% year-over-year[4] - The company's total assets as of the end of the reporting period were CNY 4,737,743,654.84, representing a 7.91% increase from CNY 4,390,641,791.92 at the end of the previous year[33] - The equity attributable to shareholders of the listed company increased to CNY 3,765,793,758.40, up 7.69% from CNY 3,496,945,092.74 year-on-year[33] - The total liabilities of the company amounted to CNY 970,128,894.57, compared to CNY 891,627,601.69 in the previous year[32] Cash Flow - The cash flow from operating activities for the first nine months of 2023 was CNY 910,354,099.44, compared to CNY 756,782,373.34 in the same period of 2022, indicating an increase of about 20.3%[10] - The net cash flow from operating activities for the third quarter of 2023 was approximately $445.65 million, an increase of 34.5% compared to $331.13 million in the same period of 2022[14] - The net cash flow from operating activities for the year-to-date was CNY 445,645,549.29, an increase of 34.58% compared to the previous year[33] - The total cash inflow from investment activities was approximately $918.29 million, down from $1.09 billion in the previous year, resulting in a net cash outflow of approximately $185.67 million from investment activities[14] - The cash inflow from financing activities was approximately $260 million, significantly higher than $79.98 million in the same quarter of the previous year[14] Research and Development - Research and development expenses for Q3 2023 were CNY 64,500,664.25, slightly down from CNY 66,951,312.19 in Q3 2022, showing a decrease of about 3.7%[5] - Research and development expenses totaled CNY 64,500,664.25 for the first three quarters, accounting for 7.80% of operating revenue, a decrease of 1.95 percentage points compared to the previous year[33] - The company invested a total of RMB 11,339,208.48 in the research of the swine pseudorabies gene engineering live vaccine, with RMB 792,521.84 invested in the current reporting period[50] - The cumulative investment in the research of the bovine infectious rhinotracheitis gene engineering live vaccine reached RMB 13,472,690.12, with RMB 320,141.25 invested in the current reporting period[50] - The company is actively pursuing new product development and market expansion through various vaccine research projects[50] Shareholder Information - The company has a total of 78,004,310 shares held by Wuhan Huazhong Agricultural University Asset Management Co., Ltd., making it one of the largest shareholders[48] - The company has signed a concerted action agreement among its top shareholders, indicating a unified control structure[48] - The company has a diverse shareholder base, with the top ten shareholders holding significant stakes, including a notable 7.87% held by Jin Meilin[55] Government and Non-Operating Income - The company reported a government subsidy of RMB 15,021,677.89, which is closely related to its normal business operations[52] - The company reported a total non-operating income of 595,205.86 and non-operating expenses of 627,514.96, resulting in a net non-operating loss of 32,309.10[54] Compliance and Challenges - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[16] - The company has emphasized the importance of adhering to its cooperative research and development framework agreement with Huazhong Agricultural University[57] - The company has faced challenges related to natural disasters, which may have impacted asset impairment provisions, although specific figures were not provided[53]